SUPN | Ticker Profile - Titan Protect

SUPN

Supernus Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · NGM

$44.75

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

10.68

Based on estimated future earnings — lower means cheaper

Rev Growth

+38.6%

Year-over-year revenue change

Profit Margin

-3.7%

How much profit the company keeps from each dollar of revenue

ROE

-2.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$64.00

+43% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 6 analysts covering this stock

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

https://www.supernus.com

Country: United States Employees: 778 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.977

Good returns relative to risk taken

Kelly Fraction

0.0819

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.360

Returns exceed worst-case losses — strong risk profile

Annual Return

33.0%

Historical annualised return based on price data

Max Drawdown

-24.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

119

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.57

Less volatile than the market — more defensive

52W High

$59.68

25% below the year high

52W Low

$30.83

45% above the year low

Avg Volume

642,455

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.51

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.80

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.96

Healthy liquidity position

Quick Ratio

1.52

Like current ratio but excludes inventory — stricter test

Gross Margin

74.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-3.6%

Profit from core operations before interest and tax

Free Cash Flow

$133M

Positive — the business generates more cash than it spends

Revenue (TTM)

$777M

Total revenue over the last 12 months

Net Income

$-29,016,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$66.00

Target Median

$64.00

Target Low

$55.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go